In a move to strengthen its pipeline of therapeutics for orphan diseases, Amicus Therapeutics has agreed to acquire privately held Scioderm for US$229 M upfront plus up to US$618 M contingent on the attainment of certain development and sales milestones. The acquisition is centred on Scioderm’s lead asset Zorblisa™, a potential first-to-market therapy for epidermolysis bullosa for which a rolling NDA submission has been agreed with the US FDA.